The Activate-Colorectal study will test the safety and efficacy of botensilimab as a standalone therapy or in combination with balstilimab for the treatment of microsatellite stable colorectal cancer, the company said.
Meanwhile, the Activate-Melanoma study will evaluate the safety and efficacy of the drug candidate as a single agent for advanced melanoma.
The company expects to launch an additional phase 2 study in pancreatic cancer later this year.
|Silo Pharma Board Authorizes $1 Million Share Buybac...|
|First Wave to Initiate Phase 2 Trial to Test Enhance...|
|Research Alert: CFRA Raises View On Shares Of The Ae...|
|European Equities Rebound in Tuesday Trading as Fran...|
|Sonoma Pharmaceuticals Signs Distribution Deal With ...|